# Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions

@article{Villemagne2018ImagingTA,
title={Imaging tau and amyloid-$\beta$ proteinopathies in Alzheimer disease and other conditions},
author={V. Villemagne and V. Dor{\'e} and S. Burnham and C. Masters and C. Rowe},
journal={Nature Reviews Neurology},
year={2018},
volume={14},
pages={225-236}
}
Most neurodegenerative disorders are associated with aggregated protein deposits. In the case of Alzheimer disease (AD), extracellular amyloid-β (Aβ) aggregates and intracellular tau neurofibrillary tangles are the two neuropathological hallmarks of the disease. Aβ-PET imaging has already been approved for clinical use and is being used in clinical trials of anti-Aβ therapies both for patient recruitment and as an outcome measure. These studies have shown that Aβ accumulation is a protracted… Expand
• Medicine
• Seminars in nuclear medicine
• 2021
This review will compare available Aβ radiotracers, discuss approaches to quantification, as well as the clinical and research applications of Aβ PET, and identify Centiloid values that correlate well with neuropathologic findings and prognosis. Expand
Sequential amyloid-β and tau accumulation foreshadows cognitive decline
• H. Wood
• Medicine
• Nature Reviews Neurology
• 2019
The findings suggest a role for 11C-PiB–PET in the detection of early AD-associated pathological changes in the brain, whereas 18F-FTP–PET is likely to be more useful for tracking disease progression and the advantages of longitudinal monitoring over crosssectional assessments. Expand
Alzheimer disease
This Primer conceives of AD biology as the brain disorder that results from a complex interplay of loss of synaptic homeostasis and dysfunction in the highly interrelated endosomal/lysosomal clearance pathways in which the precursors, aggregated species and post-translationally modified products of Aβ and tau play important roles. Expand
Dynamics of proteinopathies in Alzheimer’s disease as measured by PET and CSF biomarkers
Cross-sectional and rate of change findings suggest a temporal delay between tau pathology and synaptic impairment, and longitudinal findings suggest that the coupling between perfusion and metabolism may vary as a function of disease stage, warranting further studies. Expand
Tau Accumulation and Network Breakdown in Alzheimer's Disease.
Interestingly, a lot of magnetic resonance imaging (MRI) studies have demonstrated successive structural and functional disconnection among brain regions supporting the idea that AD is a disconnection syndrome, and recent several studies using the combination of cutting-edge Aβ and tau PET tracers integrated by data-driven statistical methods, resting-state functional MRI, and diffusion tensor imaging have shed light on the spatial distribution pattern of tau retention. Expand
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
• Medicine
• Frontiers in Aging Neuroscience
• 2021
The various PET radiotracers available for AD imaging are surveyed and discussed and their clinical applications especially in terms of early detection and cognitive relevance are discussed. Expand
Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease.
It is indicated that only three-fourths of patients diagnosed with probable AD fit the pathological criteria, suggesting that the accuracy of AD diagnosis when no biomarker evidence is available in clinical practice should be cautious. Expand
AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention.
• Medicine
• Progress in molecular biology and translational science
• 2019
This chapter summarizes the main findings on the associations of Aβ with other biomarkers of disease progression across the AD spectrum, and presents genetic and potentially modifiable lifestyle factors that might influence Aβ accumulation and therefore be targets for AD prevention. Expand
Distinct relationships of amyloid-beta and tau deposition to cerebral glucose metabolic networks in Alzheimer’s disease
The notion that amyloid-beta and tau accumulation may contribute independently to mechanisms of Alzheimer's disease is supported, and these findings might also provide connectivity evidence for the speculation that ameloid- beta deposition is protective to neuronal activity. Expand
Associations Between APOE Variants, Tau and α-Synuclein.
• Medicine
• Advances in experimental medicine and biology
• 2019
Current experimental evidence on the relationships between APOE variants, tau and α-syn, from clinical studies on fluid biomarkers and positron emission tomography (PET) imaging, and from basic experimental studies in cellular/molecular biology and animal models is described. Expand

#### References

SHOWING 1-10 OF 226 REFERENCES
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
Tau deposition in the temporal lobe more closely tracked dementia status and was a better predictor of cognitive performance than Aβ deposition in any region of the brain, supporting models of AD where tau pathology closely tracks changes in brain function that are responsible for the onset of early symptoms in AD. Expand
Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics
• Medicine
• Journal of neurochemistry
• 2006
Functional neuroimaging techniques such as functional magnetic resonance imaging, magnetic resonance spectroscopy, positron emission tomography and single photon emission computed tomography could prove to be valuable in the differential diagnosis of Alzheimer's disease, as well as in assessing prognosis. Expand
Amyloid PET Ligands for Dementia.
• Medicine
• PET clinics
• 2010
All available evidence strongly supports the notion that an imbalance between the production and removal of Aβ leading to its progressive accumulation is central to the pathogenesis of AD. Expand
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.
• Psychology, Medicine
• 2012
The application of one of the most broadly studied and widely used Aβ imaging agents, Pittsburgh Compound-B (PiB), is discussed. Expand
Tau imaging: early progress and future directions
• Psychology, Medicine
• The Lancet Neurology
• 2015
Use of selective in-vivo tau imaging will enable improved understanding of tau aggregation in the brain, facilitating research into causes, diagnosis, and treatment of major tauopathies such asExpand
Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
Use of [18F]-AV-1451 has a potential for staging of the preclinical and clinical phases of AD and the associations among β-amyloid, tau, and volume loss are assessed. Expand
Atrophy Rates in Asymptomatic Amyloidosis: Implications for Alzheimer Prevention Trials
It is concluded that hippocampal atrophy may be a feasible outcome measure for secondary prevention studies in asymptomatic amyloidosis, and recruiting 384 amyloids-positive subjects/arm will provide 80% power to detect 25% absolute slowing of hippocampa atrophy rate in an 18-month treatment trial. Expand
Is Tau Imaging More Than Just Upside-Down 18F-FDG Imaging?
• Medicine
• The Journal of Nuclear Medicine
• 2017
In several studies, a strong similarity between the distribution of tau tracer retention in the brain and the extent of hypometabolic abnormalities has been observed, which raises the question of whether tau PET has additional clinical value over established 18F-FDG PET. Expand
Distinct tau PET imaging patterns in typical and atypical Alzheimer's disease.
• Medicine, Psychology
• Brain : a journal of neurology
• 2016
The heterogeneity of tau deposition in patients with clinical variants of Alzheimer’s disease is studied by using molecular PET imaging to examine the underlying biological mechanisms in vivo and to go beyond the clinical diagnosis. Expand
Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls
A class of tau ligands, phenyl/pyridinyl-butadienyl-benzothiazoles/benZothiazoliums (PBBs), for visualizing diverse tau inclusions in brains of living patients with AD or non-AD tauopathies and animal models of these disorders are developed. Expand